219 related articles for article (PubMed ID: 34537841)
1. Ultrasensitive and Quantitative Toxin Measurement Correlates With Baseline Severity, Severe Outcomes, and Recurrence Among Hospitalized Patients With Clostridioides difficile Infection.
Alonso CD; Kelly CP; Garey KW; Gonzales-Luna AJ; Williams D; Daugherty K; Cuddemi C; Villafuerte-Gálvez J; White NC; Chen X; Xu H; Sprague R; Barrett C; Miller M; Foussadier A; Lantz A; Banz A; Pollock NR
Clin Infect Dis; 2022 Jul; 74(12):2142-2149. PubMed ID: 34537841
[TBL] [Abstract][Full Text] [Related]
2. Baseline stool toxin concentration is associated with risk of recurrence in children with
Sandora TJ; Kociolek LK; Williams DN; Daugherty K; Geer C; Cuddemi C; Chen X; Xu H; Savage TJ; Banz A; Garey KW; Gonzales-Luna AJ; Kelly CP; Pollock NR
Infect Control Hosp Epidemiol; 2023 Sep; 44(9):1403-1409. PubMed ID: 36624698
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Clostridioides difficile Stool Toxin Concentrations in Adults With Symptomatic Infection and Asymptomatic Carriage Using an Ultrasensitive Quantitative Immunoassay.
Pollock NR; Banz A; Chen X; Williams D; Xu H; Cuddemi CA; Cui AX; Perrotta M; Alhassan E; Riou B; Lantz A; Miller MA; Kelly CP
Clin Infect Dis; 2019 Jan; 68(1):78-86. PubMed ID: 29788296
[TBL] [Abstract][Full Text] [Related]
4. Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non-C. difficile Diarrhea.
Kelly CP; Chen X; Williams D; Xu H; Cuddemi CA; Daugherty K; Barrett C; Miller M; Foussadier A; Lantz A; Banz A; Pollock NR
Clin Infect Dis; 2020 Mar; 70(6):1083-1093. PubMed ID: 31211839
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection.
Lee CC; Lee JC; Chiu CW; Tsai PJ; Ko WC; Hung YP
Microbiol Spectr; 2021 Oct; 9(2):e0079921. PubMed ID: 34668727
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Cycle Threshold, Toxin Concentration, and Clinical Characteristics of Clostridioides difficile Infection in Patients with Discordant Diagnostic Test Results.
Shah MD; Balada-Llasat JM; Coe K; Reed E; Sandlund J; Pancholi P
J Clin Microbiol; 2020 Apr; 58(5):. PubMed ID: 32051264
[No Abstract] [Full Text] [Related]
7. Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection With Greater Severity and Higher Recurrence Rates.
Guh AY; Hatfield KM; Winston LG; Martin B; Johnston H; Brousseau G; Farley MM; Wilson L; Perlmutter R; Phipps EC; Dumyati GK; Nelson D; Hatwar T; Kainer MA; Paulick AL; Karlsson M; Gerding DN; McDonald LC
Clin Infect Dis; 2019 Oct; 69(10):1667-1674. PubMed ID: 30615074
[TBL] [Abstract][Full Text] [Related]
8. Changes in the Association Between Diagnostic Testing Method, Polymerase Chain Reaction Ribotype, and Clinical Outcomes From Clostridioides difficile Infection: One Institution's Experience.
Menon A; Perry DA; Motyka J; Weiner S; Standke A; Penkevich A; Keidan M; Young VB; Rao K
Clin Infect Dis; 2021 Nov; 73(9):e2883-e2889. PubMed ID: 32930705
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Clostridioides difficile Infection-Related Complications and Treatment Patterns among Nucleic Acid Amplification Test-Positive/Toxin Enzyme Immunoassay-Negative Patients.
Miller R; Morillas JA; Brizendine KD; Fraser TG
J Clin Microbiol; 2020 Feb; 58(3):. PubMed ID: 31896665
[TBL] [Abstract][Full Text] [Related]
10. Development and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantification of Clostridium difficile Toxins in Stool.
Song L; Zhao M; Duffy DC; Hansen J; Shields K; Wungjiranirun M; Chen X; Xu H; Leffler DA; Sambol SP; Gerding DN; Kelly CP; Pollock NR
J Clin Microbiol; 2015 Oct; 53(10):3204-12. PubMed ID: 26202120
[TBL] [Abstract][Full Text] [Related]
11. Stool Interleukin-1β Differentiates Clostridioides difficile Infection (CDI) From Asymptomatic Carriage and Non-CDI Diarrhea.
Villafuerte Gálvez JA; Pollock NR; Alonso CD; Chen X; Xu H; Wang L; White N; Banz A; Miller M; Daugherty K; Gonzalez-Luna AJ; Barrett C; Sprague R; Garey KW; Kelly CP
Clin Infect Dis; 2023 Feb; 76(3):e1467-e1475. PubMed ID: 35906836
[TBL] [Abstract][Full Text] [Related]
12. Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil.
Maestri AC; Raboni SM; Morales HMP; Ferrari LF; Tuon FFB; Losso A; Marconi C; Nogueira KDS
Anaerobe; 2020 Aug; 64():102238. PubMed ID: 32717474
[TBL] [Abstract][Full Text] [Related]
13. Ultrasensitive Detection of Clostridioides difficile Toxins in Stool by Use of Single-Molecule Counting Technology: Comparison with Detection of Free Toxin by Cell Culture Cytotoxicity Neutralization Assay.
Hansen G; Young S; Wu AHB; Herding E; Nordberg V; Mills R; Griego-Fullbright C; Wagner A; Ong CM; Lewis S; Yoon J; Estis J; Sandlund J; Friedland E; Carroll KC
J Clin Microbiol; 2019 Nov; 57(11):. PubMed ID: 31434724
[TBL] [Abstract][Full Text] [Related]
14. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity.
Humphries RM; Uslan DZ; Rubin Z
J Clin Microbiol; 2013 Mar; 51(3):869-73. PubMed ID: 23269736
[TBL] [Abstract][Full Text] [Related]
15. High Agreement Between an Ultrasensitive Clostridioides difficile Toxin Assay and a C. difficile Laboratory Algorithm Utilizing GDH-and-Toxin Enzyme Immunoassays and Cytotoxin Testing.
Landry ML; Topal JE; Estis J; Katzenbach P; Nolan N; Sandlund J
J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31776192
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and clinical characteristics of Clostridium difficile infection in a Korean tertiary hospital.
Kim J; Pai H; Seo MR; Kang JO
J Korean Med Sci; 2011 Oct; 26(10):1258-64. PubMed ID: 22022175
[TBL] [Abstract][Full Text] [Related]
17. Toxin A-Predominant Pathogenic Clostridioides difficile: A Novel Clinical Phenotype.
Lin Q; Pollock NR; Banz A; Lantz A; Xu H; Gu L; Gerding DN; Garey KW; Gonzales-Luna AJ; Zhao M; Song L; Duffy DC; Kelly CP; Chen X
Clin Infect Dis; 2020 Jun; 70(12):2628-2633. PubMed ID: 31400280
[TBL] [Abstract][Full Text] [Related]
18. Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era.
Polage CR; Gyorke CE; Kennedy MA; Leslie JL; Chin DL; Wang S; Nguyen HH; Huang B; Tang YW; Lee LW; Kim K; Taylor S; Romano PS; Panacek EA; Goodell PB; Solnick JV; Cohen SH
JAMA Intern Med; 2015 Nov; 175(11):1792-801. PubMed ID: 26348734
[TBL] [Abstract][Full Text] [Related]
19. VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.
Louie T; Golan Y; Khanna S; Bobilev D; Erpelding N; Fratazzi C; Carini M; Menon R; Ruisi M; Norman JM; Faith JJ; Olle B; Li M; Silber JL; Pardi DS
JAMA; 2023 Apr; 329(16):1356-1366. PubMed ID: 37060545
[TBL] [Abstract][Full Text] [Related]
20. Increased Clinical Specificity with Ultrasensitive Detection of Clostridioides difficile Toxins: Reduction of Overdiagnosis Compared to Nucleic Acid Amplification Tests.
Sandlund J; Estis J; Katzenbach P; Nolan N; Hinson K; Herres J; Pero T; Peterson G; Schumaker JM; Stevig C; Warren R; West T; Chow SK
J Clin Microbiol; 2019 Nov; 57(11):. PubMed ID: 31434726
[No Abstract] [Full Text] [Related]
[Next] [New Search]
